AL
ALUR.US Allurion Technologies, Inc.
- Market cap
- USD 1.22K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is ALUR.US undervalued?
Graham numberThe Graham number of Allurion Technologies, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Allurion Technologies, Inc. fundamental analysis
No fundamental analysis for Allurion Technologies, Inc. yet.
Allurion Technologies, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Allurion Technologies, Inc.
Allurion Technologies Inc. focuses on developing a weight loss platform for overweight people in Spain, France, Turkey, and internationally. Its Allurion Program platform offers the Allurion Smart Capsule, a swallowable and procedure-less intragastric balloon for weight loss, and access to the Allurion Virtual Care Suite, a digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program. The company is headquartered in Natick, Mass…
Full company profileAllurion Technologies, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Allurion Technologies, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 38.2M | 64.2M | 53.5M | 32.1M | 15.2M | 11.8M |
| Gross Profit | - | 29.2M | 50.7M | 41.5M | 21.5M | 9.57M | 4.92M |
| Operating Income | -5.17K | -12.5M | -32.0M | -79.1M | -50.2M | -30.2M | -14.9M |
| EBITDA | -5.15K | -8.01M | -32.3M | -69.0M | -22.2M | -27.7M | -16.3M |
| Net Income | -5.17K | -12.4M | -37.7M | -80.6M | -26.1M | -28.8M | -24.4M |
| EPS | -0.02 | -43 | -526 | -850 | -175 | -57 | -27 |
| Balance Sheet | |||||||
| Total Assets | 330K | 39.4M | 51.4M | 71.7M | 32.8M | 15.8M | 14.0M |
| Total Liabilities | 310K | 73.6M | 83.7M | 142M | 111M | 93.0M | 91.9M |
| Shareholders' Equity | 19.8K | -34.3M | -32.3M | -70.5M | -78.0M | -77.2M | -77.9M |
| Cash & Short-term Investments | 47.1K | 25.8M | 7.69M | 38.0M | 15.4M | 5.41M | 5.06M |
| Total Debt | 170K | 26.1M | 59.5M | 41.9M | 37.9M | 29.0M | 29.4M |
| Cash Flow | |||||||
| Operating Cash Flow | -35.00 | -14.3M | -47.0M | -64.0M | -42.3M | -28.9M | -12.9M |
| Capital Expenditure | 5.00 | 912K | 1.55M | 1.61M | 611K | 0.00 | 0.00 |
| Free Cash Flow | -40.00 | -15.2M | -48.5M | -65.6M | -42.9M | -28.9M | -12.9M |
| Ratios | |||||||
| ROE | -26.1% | - | - | - | - | - | - |
| ROA | -1.6% | -31.5% | -73.5% | -112.4% | -79.7% | -182.3% | -174.2% |
| Net Profit Margin | - | -32.4% | -58.8% | -150.8% | -81.4% | -188.8% | -206.8% |
| Debt to Equity | 8.57x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Allurion Technologies, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 132K | 1.84 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:25 on Jan 3, 2025.
Who owns Allurion Technologies, Inc.
- Insiders 5.18%
- Institutions 7.90%
- Public & others 86.92%
- Shares outstanding 608K
- Free float 969K
Allurion Technologies, Inc. company profile
- Company name
- Allurion Technologies, Inc.
- Ticker
- ALUR.US
- Exchange
- USA Stocks
- Listed since
- Aug 2, 2023
- Sector
- Healthcare
- Industry
- Diversified Consumer Services
- Employees
- 38
- Fiscal year end
- December
- Address
- 11 Huron Drive, Natick, MA, United States, 01760
- Phone
- 508 647 4000
- Website
- allurion.com
About Allurion Technologies, Inc.
Allurion Technologies Inc. focuses on developing a weight loss platform for overweight people in Spain, France, Turkey, and internationally. Its Allurion Program platform offers the Allurion Smart Capsule, a swallowable and procedure-less intragastric balloon for weight loss, and access to the Allurion Virtual Care Suite, a digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program. The company is headquartered in Natick, Massachusetts.
Allurion Technologies, Inc. management
6- Mr. Ojas A. BuchChief Operating Officer · born 1974
- Mr. Brendan Michael Gibbons J.D.Chief Legal & People Officer and Secretary · born 1976
- Dr. Samuel G. LevyCo-Founder · born 1983
- Dr. Ram Chuttani M.D.MD & Founding Partner · born 1961
- Ms. Alexandra van der StapVice President of Global Marketing
- Mr. Laurent LaffineurVice President of International Sales & Marketing